SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)
Hossein Borghaei, Mary W. Redman, Karen Kelly, S. Waqar, Francisco Robert, Gauri Kiefer, Philip J. Stella, Katherine Minichiello, David R. Gandara, Roy S. Herbst, Vassiliki A. Papadimitrakopoulou
Topics & Concepts
DurvalumabMedicineDocetaxelInternal medicineClinical endpointLung cancerCancerOncologySurgeryImmunotherapyClinical trialNivolumabCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies